NeuroBo Pharmaceuticals Files 8-K
Ticker: MTVA · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, pharmaceutical
TL;DR
NeuroBo Pharma filed an 8-K on 6/24. Standard disclosure.
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 24, 2024, reporting other events and financial statements. The company, formerly known as Gemphire Therapeutics Inc. until March 31, 2015, is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This filing indicates NeuroBo Pharmaceuticals is making official disclosures to the SEC, which could relate to significant corporate events or financial updates.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for 'Other Events' and financial statements, not indicating immediate significant risk.
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- Gemphire Therapeutics Inc. (company) — Former company name
- March 31, 2015 (date) — Date of name change
- June 24, 2024 (date) — Date of report
- 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138 (address) — Principal executive offices
- (857) 702-9600 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that the company is providing updated financial information or exhibits as part of this filing, though the specifics are not detailed in the provided text.
When did NeuroBo Pharmaceuticals, Inc. officially change its name from Gemphire Therapeutics Inc.?
The name change from Gemphire Therapeutics Inc. to NeuroBo Pharmaceuticals, Inc. occurred on March 31, 2015.
What is the primary business of NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where are NeuroBo Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-06-24 06:01:16
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240624x8k.htm (8-K) — 44KB
- nrbo-20240624xex99d1.htm (EX-99.1) — 31KB
- nrbo-20240624x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240624xex99d1001.jpg (GRAPHIC) — 13KB
- nrbo-20240624xex99d1002.jpg (GRAPHIC) — 32KB
- nrbo-20240624xex99d1003.jpg (GRAPHIC) — 40KB
- nrbo-20240624xex99d1004.jpg (GRAPHIC) — 40KB
- nrbo-20240624xex99d1005.jpg (GRAPHIC) — 46KB
- 0001558370-24-009415.txt ( ) — 470KB
- nrbo-20240624.xsd (EX-101.SCH) — 3KB
- nrbo-20240624_lab.xml (EX-101.LAB) — 16KB
- nrbo-20240624_pre.xml (EX-101.PRE) — 10KB
- nrbo-20240624x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On June 22, 2024, NeuroBo Pharmaceuticals, Inc. issued a press release announcing pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models. Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center, presented the data on June 22, 2024, in a poster at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21-24, in Orlando, Florida. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated June 22, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: June 24, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer